Myriad Genetics Inc (MYGN) Stock Price, Quote & News

Company Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 801 584 3600

Fax: 801 584 3640

Website: www.myriad.com

Address:

322 North 2200 West, Salt Lake City, United States

Zrahimi Aug. 18 at 6:51 PM

$MYGN back 2.85 this will rebound a bit

0 · Reply

revoltingtrees Aug. 18 at 5:14 PM

$MYGN i smell a buyout. 10k shares avg cost $2.88

0 · Reply

revoltingtrees Aug. 18 at 3:47 PM

$MYGN $NVDA

0 · Reply

revoltingtrees Aug. 14 at 6:01 PM

$MYGN first time buyer today $3.08. Selling all my $NVDA from 2009, 2012 and 2022. Its been amazing! 🤩 Thank you for the beach house in Miami!

1 · Reply

FeliciaMath Aug. 13 at 5:05 PM

$MYGN sold at 3.17. made $52 /3%

0 · Reply

Estimize Aug. 10 at 1:15 PM

Wall St is expecting -0.07 EPS for $MYGN Q1 [Reporting 10/27 AMC] http://www.estimize.com/intro/mygn?chart=historical&metric_name=eps&utm_c

0 · Reply

GoCoogs Aug. 4 at 6:47 PM

$MYGN Rebound rally in motion. Got in at 2.95.

0 · Reply

FeliciaMath Aug. 4 at 4:48 PM

bought $MYGN at 3.09

0 · Reply

theBigDollarski Aug. 3 at 7:38 PM

$MYGN this company needs to get bought out to a firm that can properly market a product and run a company. This management is horrible.

0 · Reply

AnalyticaInvestor Aug. 3 at 10:15 AM

Good morning, investors. Hyperscalers continue accelerating AI infrastructure spending, supporting demand for semiconductor suppliers, networking companies, and specialized hardware providers. Among gainers, $CIGL surged 33% on unusually heavy trading despite no company specific catalyst. On the downside, $MYGN fell 47% after disappointing quarterly results, while $CERS dropped 26% following post earnings selling pressure. Read the full Analytica Alpha 👇 https://analyticainvestor.beehiiv.com/p/yields-spike-myriad-down-47

0 · Reply

Myriad Genetics price target lowered to $3 from $5 at Stephens

Aug 8, 2026, 2:57 PM EDT - 10 days ago

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

Aug 4, 2026, 11:27 AM EDT - 14 days ago

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

2026-08-03T11:41:18.000Z - 16 days ago

Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo

2026-08-03T11:32:10.000Z - 16 days ago

Myriad Genetics price target lowered to $3.20 from $4 at BofA

2026-07-31T12:59:45.000Z - 19 days ago

Myriad Genetics price target lowered to $4 from $6 at TD Cowen

2026-07-30T20:45:44.000Z - 19 days ago

Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M

2026-07-30T20:40:31.000Z - 19 days ago

Myriad Genetics reports Q2 EPS (25c), consensus (6c)

Jul 30, 2026, 4:30 PM EDT - 19 days ago

Myriad Genetics Earnings Call Transcript: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 19 days ago

Myriad Genetics Earnings release: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 19 days ago

Myriad Genetics Slides: Q2 2026

Jul 30, 2026, 4:30 PM EDT - 19 days ago

Myriad Genetics Quarterly report: Q2 2026

Jul 30, 2026, 4:05 PM EDT - 19 days ago

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Jul 23, 2026, 9:05 AM EDT - 27 days ago

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Jul 21, 2026, 9:05 AM EDT - 4 weeks ago

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Jul 2, 2026, 9:05 AM EDT - 6 weeks ago

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer

Jun 23, 2026, 9:05 AM EDT - 2 months ago

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Myriad Genetics Transcript: AGM 2026

2026-06-02T14:16:51.000Z - 2 months ago

Myriad Genetics appoints Raj Jampa as chief technology officer

Jun 2, 2026, 9:05 AM EDT - 2 months ago

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

May 27, 2026, 9:05 AM EDT - 3 months ago

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

2026-05-26T20:39:25.000Z - 3 months ago

Myriad Genetics launches Prolaris + AI

May 26, 2026, 4:05 PM EDT - 3 months ago

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

May 15, 2026, 11:00 AM EDT - 3 months ago

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

May 7, 2026, 4:05 PM EDT - 3 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

2026-05-07T05:11:29.000Z - 3 months ago

Myriad Genetics price target lowered to $6 from $7 at TD Cowen

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Myriad Genetics Quarterly report: Q1 2026

May 5, 2026, 4:05 PM EDT - 3 months ago

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Apr 30, 2026, 9:05 AM EDT - 3 months ago

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Apr 28, 2026, 4:05 PM EDT - 4 months ago

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

2026-04-16T13:42:01.000Z - 4 months ago

Myriad Genetics to deliver six abstracts at AACR 2026

Apr 16, 2026, 9:15 AM EDT - 4 months ago

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Apr 14, 2026, 9:15 AM EDT - 4 months ago

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Myriad Genetics Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Myriad Genetics Proxy statement: Proxy filing

Apr 9, 2026, 9:15 AM EDT - 4 months ago

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

2026-03-17T20:20:19.000Z - 5 months ago

Myriad Genetics announces FDA approval for MyChoice CDx Test

Mar 17, 2026, 4:05 PM EDT - 5 months ago

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Mar 10, 2026, 1:40 PM EDT - 5 months ago

Myriad Genetics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 3:10 PM EST - 6 months ago

Myriad Genetics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-24T21:25:02.000Z - 6 months ago

Myriad Genetics files $200M mixed securities shelf

2026-02-24T14:07:41.000Z - 6 months ago

Myriad Genetics to present six abstracts at ASCO-GU 2026

2026-02-24T13:02:15.000Z - 6 months ago

Myriad Genetics price target lowered to $6 from $8 at UBS

Feb 24, 2026, 7:00 AM EST - 6 months ago

Myriad Genetics Registration statement: Registration Filing

2026-02-24T11:40:44.000Z - 6 months ago

Myriad Genetics price target lowered to $6 from $6.50 at Wells Fargo

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Myriad Genetics Slides: Q4 2025

2026-02-23T21:28:16.000Z - 6 months ago

Myriad Genetics sees Q1 revenue $200M-$203M, consensus $211.19M

2026-02-23T21:26:37.000Z - 6 months ago

Myriad Genetics backs FY26 revenue view $860M-$880M, consensus $868.06M

2026-02-23T21:15:56.000Z - 6 months ago

Myriad Genetics reports Q4 adjusted EPS 4c, consensus (2c)

Feb 23, 2026, 4:05 PM EST - 6 months ago

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

2026-02-19T14:24:04.000Z - 6 months ago

Myriad announce publication of validation of FirstGene Multiple Prenatal Screen

Feb 19, 2026, 9:15 AM EST - 6 months ago

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 16, 2026, 4:15 PM EST - 6 months ago

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Jan 14, 2026, 8:15 PM EST - 7 months ago

Myriad Genetics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 7 months ago

Myriad Genetics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:30 AM EST - 7 months ago

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Jan 5, 2026, 4:15 PM EST - 8 months ago

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 12:00 PM EST - 9 months ago

Myriad Genetics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:15 PM EST - 9 months ago

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Nov 18, 2025, 1:20 PM EST - 9 months ago

Myriad Genetics Transcript: Wolfe Research Healthcare Conference 2025

Nov 11, 2025, 9:00 AM EST - 10 months ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Myriad Genetics Slides: Q3 2025

Nov 3, 2025, 4:05 PM EST - 10 months ago

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Oct 31, 2025, 9:05 AM EDT - 10 months ago

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

Oct 27, 2025, 4:15 PM EDT - 10 months ago

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

Oct 8, 2025, 5:21 PM EDT - 11 months ago

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

Sep 23, 2025, 8:01 AM EDT - 11 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Sep 23, 2025, 8:00 AM EDT - 11 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SOPH

Sep 10, 2025, 7:45 AM EDT - 1 year ago

Myriad Genetics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 7:00 PM EDT - 1 year ago

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

Sep 4, 2025, 3:45 PM EDT - 1 year ago

Myriad Genetics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 4:30 PM EDT - 1 year ago

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Aug 13, 2025, 8:00 AM EDT - 1 year ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Myriad Genetics Slides: Q2 2025

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Myriad Genetics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 10:00 AM EDT - 1 year ago

Myriad Genetics Transcript: AGM 2025

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

May 27, 2025, 4:05 PM EDT - 1 year ago

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Zrahimi Aug. 18 at 6:51 PM

$MYGN back 2.85 this will rebound a bit

0 · Reply

revoltingtrees Aug. 18 at 5:14 PM

$MYGN i smell a buyout. 10k shares avg cost $2.88

0 · Reply

revoltingtrees Aug. 18 at 3:47 PM

$MYGN $NVDA

0 · Reply

revoltingtrees Aug. 14 at 6:01 PM

$MYGN first time buyer today $3.08. Selling all my $NVDA from 2009, 2012 and 2022. Its been amazing! 🤩 Thank you for the beach house in Miami!

1 · Reply

FeliciaMath Aug. 13 at 5:05 PM

$MYGN sold at 3.17. made $52 /3%

0 · Reply

Estimize Aug. 10 at 1:15 PM

Wall St is expecting -0.07 EPS for $MYGN Q1 [Reporting 10/27 AMC] http://www.estimize.com/intro/mygn?chart=historical&metric_name=eps&utm_c

0 · Reply

GoCoogs Aug. 4 at 6:47 PM

$MYGN Rebound rally in motion. Got in at 2.95.

0 · Reply

FeliciaMath Aug. 4 at 4:48 PM

bought $MYGN at 3.09

0 · Reply

theBigDollarski Aug. 3 at 7:38 PM

$MYGN this company needs to get bought out to a firm that can properly market a product and run a company. This management is horrible.

0 · Reply

AnalyticaInvestor Aug. 3 at 10:15 AM

0 · Reply

ShKumaresan Aug. 3 at 3:12 AM

$RBLX $HTZ $MYGN Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week? https://stocktwits.com/news-articles/default/equity/why-did-rblx-htz-mygn-stocks-plunge-to-52-week-lows-last-week/cZoRyOBRJ5n

0 · Reply

StocktwitsNews Aug. 3 at 3:12 AM

Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week? $RBLX $HTZ $MYGN https://stocktwits.com/news/equity/markets/why-did-rblx-htz-mygn-stocks-plunge-to-52-week-lows-last-week/cZoRyOBRJ5n

0 · Reply

JustBen47 Aug. 1 at 6:34 PM

$MYGN Not looking good at all

0 · Reply

Ric_1M Aug. 1 at 2:18 PM

$KPTI $BIOA $NUWE $DFNS $MYGN “Our greatest weakness lies in giving up. The most certain way to succeed is always to try just one more time.” Thomas Edison

0 · Reply

james899 Jul. 31 at 8:50 PM

$MYGN woah what's going on, bankruptcy incoming?

0 · Reply